Cash flow Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 29/08/2026 am IST			5-day change	1st Jan Change
13.38 ^USD	-6.56%		-6.43%	-14.67%

24/08	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
24/08	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

7cd0004a225f822c22951504a.-LtgRrDeuZlDn0yhIor0Mm8Vb5JJoYvFyELn9ywIyQA.q8wWDePoiego2CjvT-ijZyxlLOYM1f28qw6TrXhkjU666FIw6bP79wvNKw

Published financial data: MONTE ROSA THERAPEUTICS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Revenues	-	-	-	7.56Cr	12Cr
Total Revenues	-	-	-	7.56Cr	12Cr
Cost of Goods Sold, Total	-	-	-	11Cr	13Cr
Gross Profit	-	-	-	-3.72Cr	-1Cr
Selling General & Admin Expenses, Total	1.57Cr	3.51Cr	3.99Cr	4.39Cr	4.42Cr
R&D Expenses	5.72Cr	7.73Cr	10Cr	-	-
Other Operating Expenses, Total	7.29Cr	11Cr	14Cr	4.39Cr	4.42Cr
Operating Income	-7.29Cr	-11Cr	-14Cr	-8.11Cr	-5.42Cr
Interest Expense, Total	-	-	-	-	-
Interest And Investment Income	46T	37.64L	93.34L	1.06Cr	1.29Cr
Net Interest Expenses	46T	37.64L	93.34L	1.06Cr	1.29Cr
Currency Exchange Gains (Loss)	-2L	10T	-9L	4L	14.84L
Other Non Operating Income (Expenses)	-10L	-	-	-	-
EBT, Excl. Unusual Items	-7.4Cr	-11Cr	-13Cr	-7.01Cr	-3.98Cr
Gain (Loss) On Sale Of Investments	-	-	-1L	-	-
Gain (Loss) On Sale Of Assets	-	1L	24T	-	59T
EBT, Incl. Unusual Items	-7.4Cr	-11Cr	-14Cr	-7.01Cr	-3.97Cr
Income Tax Expense	-	-	3L	25.7L	-10.97L
Earnings From Continuing Operations	-7.4Cr	-11Cr	-14Cr	-7.27Cr	-3.86Cr
Net Income to Company	-7.4Cr	-11Cr	-14Cr	-7.27Cr	-3.86Cr
Net Income - (IS)	-7.4Cr	-11Cr	-14Cr	-7.27Cr	-3.86Cr
Net Income to Common Incl Extra Items	-7.4Cr	-11Cr	-14Cr	-7.27Cr	-3.86Cr
Net Income to Common Excl. Extra Items	-7.4Cr	-11Cr	-14Cr	-7.27Cr	-3.86Cr
Per Share Items
Net EPS - Basic	-2.96	-2.3	-2.63	-0.98	-0.46
Basic EPS - Continuing Operations	-2.96	-2.3	-2.63	-0.98	-0.46
Basic Weighted Average Shares Outstanding	2.5Cr	4.72Cr	5.14Cr	7.39Cr	8.31Cr
Net EPS - Diluted	-2.96	-2.3	-2.63	-0.98	-0.46
Diluted EPS - Continuing Operations	-2.96	-2.3	-2.63	-0.98	-0.46
Diluted Weighted Average Shares Outstanding	2.5Cr	4.72Cr	5.14Cr	7.39Cr	8.31Cr
Normalized Basic EPS	-1.85	-1.44	-1.64	-0.59	-0.3
Normalized Diluted EPS	-1.85	-1.44	-1.64	-0.59	-0.3
Supplemental Items
EBITDA	-7.08Cr	-11Cr	-14Cr	-7.3Cr	-4.59Cr
EBITA	-7.29Cr	-11Cr	-14Cr	-8.11Cr	-5.42Cr
EBIT	-7.29Cr	-11Cr	-14Cr	-8.11Cr	-5.42Cr
EBITDAR	-6.84Cr	-9.98Cr	-13Cr	-6.25Cr	-3.66Cr
Effective Tax Rate - (Ratio)	-	-	-0.25	-3.66	2.76
Current Domestic Taxes	-	-	-	-	-10.97L
Total Current Taxes	-	-	-	-	-10.97L
Normalized Net Income	-4.62Cr	-6.79Cr	-8.43Cr	-4.38Cr	-2.49Cr
Non-Cash Pension Expense	0	19T	2L	2L	1L
Supplemental Operating Expense Items
General and Administrative Expenses	1.57Cr	2.63Cr	3.05Cr	3.34Cr	3.5Cr
Research And Development Expense From Footnotes	5.72Cr	8.51Cr	11Cr	12Cr	14Cr
Net Rental Expense, Total	23L	88.22L	94.58L	1.05Cr	92.2L
Stock-Based Comp., COGS (Total)	-	-	-	1.06Cr	1.09Cr
Stock-Based Comp., R&D Exp. (Total)	26.06L	55.82L	89.39L	-	-
Stock-Based Comp., G&A Exp. (Total)	25.94L	60.82L	77.3L	74.97L	80.05L
Total Stock-Based Compensation	52L	1.17Cr	1.67Cr	1.81Cr	1.89Cr

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Assets
Cash And Equivalents	35Cr	5.49Cr	13Cr	22Cr	13Cr
Short Term Investments	-	21Cr	10Cr	15Cr	25Cr
Total Cash And Short Term Investments	35Cr	26Cr	23Cr	37Cr	38Cr
Other Receivables	-	76.56L	5L	2L	1.16Cr
Total Receivables	-	76.56L	5L	2L	1.16Cr
Prepaid Expenses	25.95L	44.44L	32.94L	51.18L	44.81L
Restricted Cash	-	10L	-	-	-
Total Current Assets	35Cr	28Cr	24Cr	38Cr	39Cr
Gross Property Plant And Equipment	1.5Cr	6.82Cr	7.49Cr	7.67Cr	7.8Cr
Accumulated Depreciation	-27.03L	-62.51L	-1.22Cr	-2.04Cr	-2.76Cr
Net Property Plant And Equipment	1.23Cr	6.19Cr	6.26Cr	5.63Cr	5.04Cr
Other Long-Term Assets, Total	53.38L	45.96L	49.32L	49.78L	51.02L
Total Assets	37Cr	34Cr	30Cr	44Cr	45Cr
Liabilities
Accounts Payable, Total	65.58L	78.62L	1.12Cr	1.72Cr	35.5L
Accrued Expenses, Total	92.4L	95.6L	1.29Cr	1.54Cr	2.51Cr
Short-term Borrowings	-	-	-	-	-
Current Portion of Leases	-	31.27L	31.62L	37.14L	43.97L
Unearned Revenue Current, Total	-	-	1.77Cr	12Cr	2.96Cr
Other Current Liabilities	8L	50.2L	16.71L	33.54L	15.78L
Total Current Liabilities	1.66Cr	2.56Cr	4.66Cr	16Cr	6.42Cr
Long-Term Leases	-	4.39Cr	4.29Cr	3.9Cr	3.48Cr
Unearned Revenue Non Current	-	-	3.23Cr	1.61Cr	11Cr
Pension & Other Post Retirement Benefits	21.76L	15.33L	27.13L	37.02L	52.65L
Total Liabilities	1.88Cr	7.1Cr	12Cr	22Cr	22Cr
Preferred Stock Convertible	-	-	-	-	-
Total Preferred Equity	-	-	-	-	-
Common Stock, Total	5T	5T	5T	6T	7T
Additional Paid In Capital	47Cr	50Cr	55Cr	66Cr	71Cr
Retained Earnings	-12Cr	-23Cr	-37Cr	-44Cr	-48Cr
Comprehensive Income and Other	-20.21L	-17.52L	-27.24L	-33.56L	-38.27L
Total Common Equity	35Cr	27Cr	18Cr	22Cr	23Cr
Total Equity	35Cr	27Cr	18Cr	22Cr	23Cr
Total Liabilities And Equity	37Cr	34Cr	30Cr	44Cr	45Cr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	4.64Cr	4.92Cr	5.01Cr	6.15Cr	8Cr
ECS Total Common Shares Outstanding	4.65Cr	4.93Cr	5.01Cr	6.15Cr	6.55Cr
Book Value / Share	7.47	5.5	3.57	3.62	3.56
Tangible Book Value	35Cr	27Cr	18Cr	22Cr	23Cr
Tangible Book Value Per Share	7.47	5.5	3.57	3.62	3.56
Total Debt	0	4.7Cr	4.6Cr	4.27Cr	3.92Cr
Net Debt	-35Cr	-22Cr	-19Cr	-33Cr	-34Cr
Debt Equivalent of Unfunded Proj. Benefit Obligation	21.76L	15.33L	27.13L	37.02L	52.65L
Debt Equivalent Oper. Leases	1.84Cr	7.06Cr	7.57Cr	8.36Cr	7.38Cr
Account Code - Inventory Valuation	3	3	3	3	3
Machinery, Total	1.31Cr	1.87Cr	2.42Cr	2.74Cr	2.98Cr
Full Time Employees	93	123	133	134	150

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Net Income	-7.4Cr	-11Cr	-14Cr	-7.27Cr	-3.86Cr
Depreciation & Amortization - CF	21.32L	37.45L	62.22L	1.02Cr	1.09Cr
Depreciation & Amortization, Total	21.32L	37.45L	62.22L	1.02Cr	1.09Cr
(Gain) Loss From Sale Of Asset	17T	-1L	-24T	-	-59T
(Gain) Loss on Sale of Investments - (CF)	-	-19.45L	-37.83L	-29.48L	-21.45L
Stock-Based Compensation (CF)	52L	1.17Cr	1.67Cr	1.81Cr	1.89Cr
Other Operating Activities, Total	10L	48.14L	-	-21L	-25L
Change In Accounts Receivable	-	-2L	18.97L	3L	-44.27L
Change In Accounts Payable	-7L	-7L	57.58L	62.52L	-1.37Cr
Change in Unearned Revenues	-	-	5Cr	8.34Cr	75.24L
Change in Other Net Operating Assets	69.92L	-12.03L	1.48Cr	14.35L	14.22L
Cash from Operations	-5.94Cr	-9.25Cr	-4.38Cr	4.2Cr	-2.28Cr
Capital Expenditure	-97.32L	-1.29Cr	-1.9Cr	-39.88L	-47L
Sale of Property, Plant, and Equipment	79T	1L	62T	-	-
Investment in Marketable and Equity Securities, Total	-	-21Cr	11Cr	-4.05Cr	-9.71Cr
Cash from Investing	-96.53L	-22Cr	8.88Cr	-4.45Cr	-10Cr
Short Term Debt Issued, Total	-	-	-	-	-
Total Debt Issued	-	-	-	-	-
Issuance of Common Stock	26Cr	2.08Cr	26.08L	5.25Cr	3.07Cr
Issuance of Preferred Stock	14Cr	-	-	-	-
Other Financing Activities, Total	-2.12Cr	-4L	2.49Cr	4.64Cr	-4L
Cash from Financing	38Cr	2.05Cr	2.75Cr	9.89Cr	3.04Cr
Net Change in Cash	31Cr	-29Cr	7.25Cr	9.64Cr	-9.43Cr
Supplemental Items
Levered Free Cash Flow	-6.13Cr	-7.24Cr	-5.55Cr	8.2Cr	-11Cr
Unlevered Free Cash Flow	-6.13Cr	-7.24Cr	-5.55Cr	8.2Cr	-11Cr
Change In Net Working Capital	1.33Cr	46.61L	-3.02Cr	-11Cr	10Cr
Net Debt Issued / Repaid	-	-	-	-	-

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Profitability
Return on Assets	-21.92	-19.82	-27.72	-13.66	-7.64
Return on Total Capital	-24.85	-21.1	-32.95	-20.65	-12.6
Return On Equity %	-40.35	-35.06	-60.07	-36.15	-16.94
Return on Common Equity	-49.51	-35.06	-60.07	-36.15	-16.94
Margin Analysis
Gross Profit Margin %	-	-	-	-49.25	-8.11
SG&A Margin	-	-	-	58.01	35.72
EBITDA Margin %	-	-	-	-96.52	-37.08
EBITA Margin %	-	-	-	-107.26	-43.83
EBIT Margin %	-	-	-	-107.26	-43.83
Income From Continuing Operations Margin %	-	-	-	-96.14	-31.23
Net Income Margin %	-	-	-	-96.14	-31.23
Net Avail. For Common Margin %	-	-	-	-96.14	-31.23
Normalized Net Income Margin	-	-	-	-57.96	-20.1
Levered Free Cash Flow Margin	-	-	-	108.4	-91.42
Unlevered Free Cash Flow Margin	-	-	-	108.4	-91.42
Asset Turnover
Asset Turnover	-	-	-	0.2	0.28
Fixed Assets Turnover	-	-	-	1.27	2.32
Short Term Liquidity
Current Ratio	20.96	10.79	5.07	2.4	6.12
Quick Ratio	20.8	10.58	5	2.37	6.05
Operating Cash Flow to Current Liabilities	-3.57	-3.62	-0.94	0.27	-0.36
Average Days Payable Outstanding	-	-	-	46	28.34
Long Term Solvency
Total Debt/Equity	-	17.32	25.68	19.16	16.82
Total Debt / Total Capital	-	14.76	20.44	16.08	14.4
LT Debt/Equity	-	16.16	23.92	17.49	14.93
Long-Term Debt / Total Capital	-	13.78	19.03	14.68	12.78
Total Liabilities / Total Assets	5.14	20.73	40.99	49.19	48.05
EBIT / Interest Expense	-	-	-	-	-
EBITDA / Interest Expense	-	-	-	-	-
(EBITDA - Capex) / Interest Expense	-	-	-	-	-
Total Debt / EBITDA	-	-0.47	-0.36	-0.68	-1.07
Net Debt / EBITDA	4.89	2.16	1.46	5.27	9.22
Total Debt / (EBITDA - Capex)	-	-0.42	-0.31	-0.64	-0.95
Net Debt / (EBITDA - Capex)	4.3	1.91	1.27	4.95	8.18
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-	-	-	-	63.54
Gross Profit, 1 Yr. Growth %	-	-	-	-63.97	-73.07
EBITDA, 1 Yr. Growth %	157.53	53.55	26.19	-46.76	-37.18
EBITA, 1 Yr. Growth %	160.2	54.2	27.52	-43.4	-33.17
EBIT, 1 Yr. Growth %	160.2	54.2	27.52	-43.4	-33.17
Earnings From Cont. Operations, 1 Yr. Growth %	106.13	46.71	24.75	-46.29	-46.87
Net Income, 1 Yr. Growth %	106.13	46.71	24.75	-46.29	-46.87
Normalized Net Income, 1 Yr. Growth %	106.13	46.85	24.21	-48.02	-43.27
Diluted EPS Before Extra, 1 Yr. Growth %	-87.49	-22.34	14.63	-62.65	-52.73
Net Property, Plant and Equip., 1 Yr. Growth %	166.6	402.29	1.14	-10.06	-10.55
Total Assets, 1 Yr. Growth %	641.89	-6.54	-11.28	44.44	2.26
Tangible Book Value, 1 Yr. Growth %	-813.17	-21.9	-33.96	24.37	4.54
Common Equity, 1 Yr. Growth %	-813.17	-21.9	-33.96	24.37	4.54
Cash From Operations, 1 Yr. Growth %	157.51	55.76	-52.63	-195.88	-154.29
Capital Expenditures, 1 Yr. Growth %	187.16	32.67	47.48	-79.06	17.85
Levered Free Cash Flow, 1 Yr. Growth %	-906.38	18.13	-23.39	-253.59	-237.93
Unlevered Free Cash Flow, 1 Yr. Growth %	-906.38	18.13	-23.39	-253.59	-237.93
Compound Annual Growth Rate Over Two Years
Gross Profit, 2 Yr. CAGR %	-	-	-	-	-68.85
EBITDA, 2 Yr. CAGR %	-13.73	98.86	39.2	-18.03	-42.17
EBITA, 2 Yr. CAGR %	-12.84	100.31	40.23	-15.04	-38.5
EBIT, 2 Yr. CAGR %	-12.84	100.31	40.23	-15.04	-38.5
Earnings From Cont. Operations, 2 Yr. CAGR %	-10.77	73.9	35.28	-18.14	-46.58
Net Income, 2 Yr. CAGR %	-10.77	73.9	35.28	-18.14	-46.58
Normalized Net Income, 2 Yr. CAGR %	-10.77	73.99	35.06	-19.64	-45.7
Diluted EPS Before Extra, 2 Yr. CAGR %	-78.76	-68.83	-5.65	-34.57	-57.98
Net Property, Plant and Equip., 2 Yr. CAGR %	203.85	265.94	125.39	-4.62	-10.3
Total Assets, 2 Yr. CAGR %	474.63	163.33	-8.94	13.2	21.53
Tangible Book Value, 2 Yr. CAGR %	434.85	136.01	-28.18	-9.37	14.03
Common Equity, 2 Yr. CAGR %	434.85	136.01	-28.18	-9.37	14.03
Cash From Operations, 2 Yr. CAGR %	-10.48	100.28	-14.1	-32.61	-27.86
Capital Expenditures, 2 Yr. CAGR %	-23.48	95.18	39.88	-44.42	-50.32
Levered Free Cash Flow, 2 Yr. CAGR %	-	208.64	-4.87	6.4	45.55
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	208.64	-4.87	6.4	45.55
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	-	4.55	70.88	1.04	-24.99
EBITA, 3 Yr. CAGR %	-	5.42	72.31	3.63	-21.58
EBIT, 3 Yr. CAGR %	-	5.42	72.31	3.63	-21.58
Earnings From Cont. Operations, 3 Yr. CAGR %	-	5.32	55.67	-0.57	-29.13
Net Income, 3 Yr. CAGR %	-	5.32	55.67	-0.57	-29.13
Normalized Net Income, 3 Yr. CAGR %	-	5.35	55.5	-1.76	-28.45
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-67.28	-51.89	-30.72	-41.29
Net Property, Plant and Equip., 3 Yr. CAGR %	-	259.27	138.36	65.94	-6.64
Total Assets, 3 Yr. CAGR %	-	213.67	83.23	6.2	9.43
Tangible Book Value, 3 Yr. CAGR %	-	181.65	54.37	-13.75	-4.95
Common Equity, 3 Yr. CAGR %	-	181.65	54.37	-13.75	-4.95
Cash From Operations, 3 Yr. CAGR %	-	7.67	23.86	-10.9	-37.29
Capital Expenditures, 3 Yr. CAGR %	-	-8.07	77.78	-25.72	-28.6
Levered Free Cash Flow, 3 Yr. CAGR %	-	-	93.97	10.18	16.02
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	-	93.97	10.18	16.02
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	-	-	-	-5.15	10.79
EBITA, 5 Yr. CAGR %	-	-	-	-3.3	14.12
EBIT, 5 Yr. CAGR %	-	-	-	-3.3	14.12
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	-	-4.78	1.49
Net Income, 5 Yr. CAGR %	-	-	-	-4.78	1.49
Normalized Net Income, 5 Yr. CAGR %	-	-	-	-5.46	2.09
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-	-56.83	-54.43
Net Property, Plant and Equip., 5 Yr. CAGR %	-	-	-	111.36	61.23
Total Assets, 5 Yr. CAGR %	-	-	-	108.65	55.48
Tangible Book Value, 5 Yr. CAGR %	-	-	-	78.95	36.75
Common Equity, 5 Yr. CAGR %	-	-	-	78.95	36.75
Cash From Operations, 5 Yr. CAGR %	-	-	-	-10.73	-0.22
Capital Expenditures, 5 Yr. CAGR %	-	-	-	-24.83	6.76
Levered Free Cash Flow, 5 Yr. CAGR %	-	-	-	-	71.59
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	-	-	-	71.59